For example, the clinical activity of sacituzumab govitecan (i.e., Trodelvy, Gilead Science Inc., Foster City, CA), an ADC targeting TROP2 currently approved by the FDA for the treatment of breast and bladder cancer, is currently being evaluated against platinum-resistant ovarian cancer patients in a Phase II Investigator-Initiated clinical trial at Yale University (NCT06028932). Here, TACSTD2 is linked to ovarian carcinoma.